Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2025)

Historic Non Operating Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $4.3 million.

  • 4D Molecular Therapeutics' Non Operating Income fell 4088.35% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 1483.77%. This contributed to the annual value of $27.0 million for FY2024, which is 12421.45% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Non Operating Income of $4.3 million as of Q3 2025, which was down 4088.35% from $4.8 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Non Operating Income high stood at $7.5 million for Q2 2024, and its period low was -$456000.0 during Q4 2021.
  • Over the past 5 years, 4D Molecular Therapeutics' median Non Operating Income value was $2.5 million (recorded in 2023), while the average stood at $3.0 million.
  • In the last 5 years, 4D Molecular Therapeutics' Non Operating Income plummeted by 18632.48% in 2021 and then soared by 475714.29% in 2022.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Non Operating Income stood at -$456000.0 in 2021, then soared by 394.08% to $1.3 million in 2022, then surged by 225.8% to $4.4 million in 2023, then skyrocketed by 47.54% to $6.4 million in 2024, then crashed by 33.15% to $4.3 million in 2025.
  • Its Non Operating Income stands at $4.3 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.6 million for Q1 2025.